JP2022537359A5 - - Google Patents

Info

Publication number
JP2022537359A5
JP2022537359A5 JP2021575366A JP2021575366A JP2022537359A5 JP 2022537359 A5 JP2022537359 A5 JP 2022537359A5 JP 2021575366 A JP2021575366 A JP 2021575366A JP 2021575366 A JP2021575366 A JP 2021575366A JP 2022537359 A5 JP2022537359 A5 JP 2022537359A5
Authority
JP
Japan
Prior art keywords
chain variable
variable domain
amino acid
tcr
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021575366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537359A (ja
JP7730765B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038142 external-priority patent/WO2020257288A2/en
Publication of JP2022537359A publication Critical patent/JP2022537359A/ja
Publication of JP2022537359A5 publication Critical patent/JP2022537359A5/ja
Priority to JP2024135124A priority Critical patent/JP2024164066A/ja
Priority to JP2025135733A priority patent/JP2025166209A/ja
Application granted granted Critical
Publication of JP7730765B2 publication Critical patent/JP7730765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021575366A 2019-06-18 2020-06-17 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 Active JP7730765B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024135124A JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025135733A JP2025166209A (ja) 2019-06-18 2025-08-18 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862726P 2019-06-18 2019-06-18
US62/862,726 2019-06-18
US201962871793P 2019-07-09 2019-07-09
US62/871,793 2019-07-09
PCT/US2020/038142 WO2020257288A2 (en) 2019-06-18 2020-06-17 Mage-a4 t cell receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135124A Division JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022537359A JP2022537359A (ja) 2022-08-25
JP2022537359A5 true JP2022537359A5 (https=) 2023-06-23
JP7730765B2 JP7730765B2 (ja) 2025-08-28

Family

ID=74040867

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021575366A Active JP7730765B2 (ja) 2019-06-18 2020-06-17 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2024135124A Pending JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025135733A Pending JP2025166209A (ja) 2019-06-18 2025-08-18 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024135124A Pending JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025135733A Pending JP2025166209A (ja) 2019-06-18 2025-08-18 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Country Status (15)

Country Link
US (1) US20220324939A1 (https=)
EP (1) EP3986938A4 (https=)
JP (3) JP7730765B2 (https=)
KR (1) KR20220035387A (https=)
CN (2) CN118994364A (https=)
AU (1) AU2020295401A1 (https=)
BR (1) BR112021025548A2 (https=)
CA (1) CA3144253A1 (https=)
CL (2) CL2021003366A1 (https=)
CO (1) CO2022000281A2 (https=)
IL (1) IL289042A (https=)
MA (1) MA56548A (https=)
MX (1) MX2021015946A (https=)
PH (1) PH12021553152A1 (https=)
WO (1) WO2020257288A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG11201901634UA (en) * 2016-09-23 2019-04-29 Lion Tcr Pte Ltd An hbv antigen specific binding molecules and fragments thereof
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
EP4422651A4 (en) * 2021-10-25 2025-12-17 Univ Texas PEPTIDES AND MANIPULATED T-CELL RECEPTORS FOR TARGETTING THE MAGE-A4 ANTIGEN AND METHOD FOR USE
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023238125A1 (en) * 2022-06-08 2023-12-14 Sheba Impact Ltd. Virus-specific recombinant t cell receptors and t cells comprising them
JP2025525382A (ja) * 2022-06-24 2025-08-05 アムジエン・インコーポレーテツド Ｍａｇｅａ４特異的ｔ細胞受容体
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
JP2026509947A (ja) 2022-10-31 2026-03-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法
EP4393942A1 (en) * 2022-12-29 2024-07-03 Keshihua (Nanjing) Biotechnology Co., Ltd Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN119569851A (zh) * 2023-09-05 2025-03-07 香雪生命科学技术（广东）有限公司 针对magea4的高亲和力tcr
WO2025233432A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SMT202200306T1 (it) * 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
BR112018070637A2 (pt) * 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022537359A5 (https=)
JP2022505679A5 (https=)
JP2022518925A5 (https=)
CN112739379B (zh) 包含OX40抗原结合位点的Fc结合片段
JP2020501531A5 (https=)
ES2387809T3 (es) Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
JP5723279B2 (ja) 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用
JP2023511417A5 (https=)
JP2016527286A5 (https=)
JP2021508255A5 (https=)
RU2019138067A (ru) Биспецифическое антитело против ox40 и ctla-4
CN114729053B (zh) 一种4-1bb结合蛋白及其应用
JP2022533418A (ja) 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子
JP2013527761A5 (https=)
JP2022548764A5 (https=)
JP2024521405A (ja) Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質
JP2022538475A5 (https=)
JP2023530036A5 (https=)
CN115768467A (zh) 用于治疗癌症和感染的针对NKp46的抗体及其构建体
CN114616251B (zh) 靶向PD-1和TGFβ的重组蛋白
US12559538B2 (en) PD-1 polypeptide variants
US9499622B2 (en) Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins
JP2024533457A5 (https=)
EP4274852A2 (en) Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
JP2022513405A5 (https=)